My NCBI | Sign In
RSS Settings
  • Search: Gathe Joseph[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 25

    1.

    Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).

    Ross L, Elion R, Lanier R, Dejesus E, Cohen C, Redfield RR, Gathe JC, Hsu RK, Yau L, Paulsen D, Ha B; COL40263 Study Team.

    AIDS Res Hum Retroviruses. 2009 Jul;25(7):665-72.PMID: 19563238 [PubMed - indexed for MEDLINE]Related articles

    2.

    Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

    Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, Klein CE, Chiu YL, King MS, Bernstein BM.

    AIDS Res Hum Retroviruses. 2009 Mar;25(3):269-75.PMID: 19292590 [PubMed - indexed for MEDLINE]Related articles

    3.

    A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

    Gathe J, da Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B.

    J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):474-81.PMID: 19225400 [PubMed - indexed for MEDLINE]Related articles

    4.

    Cord blood stem cell therapy for acquired immune deficiency syndrome.

    Behringer RR, Gonzalez G, Shpall EJ, Gathe J.

    Stem Cells Dev. 2008 Nov 19. [Epub ahead of print]PMID: 19018697 [PubMed - as supplied by publisher]Related articles

    5.

    Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.

    DeJesus E, Gottlieb MS, Gathe JC Jr, Greenberg ML, Guittari CJ, Zolopa AR.

    Antimicrob Agents Chemother. 2008 Dec;52(12):4315-9. Epub 2008 Sep 22.PMID: 18809940 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Antiretroviral rounds. Resistance: what you don't know--can it hurt you?

    Gathe JC Jr, Elion R.

    AIDS Clin Care. 2008 Jun;20(6):51-2. No abstract available. PMID: 18661634 [PubMed - indexed for MEDLINE]Related articles

    7.

    Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS.

    Gathe JC Jr, Mayberry C, Clemmons J, Nemecek J.

    J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):363-4. No abstract available. PMID: 18580340 [PubMed - indexed for MEDLINE]Related articles

    8.

    Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens.

    Huang IC, Wu AW, Finnern HW, Thijs H, Gathe JC, Fairclough DL.

    Antivir Ther. 2008;13(1):15-25.PMID: 18389895 [PubMed - indexed for MEDLINE]Related articles

    9.

    Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center.

    Gathe J.

    Curr Med Res Opin. 2008 Mar;24(3):769-73. Epub 2008 Jan 29.PMID: 18234149 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.

    Gathe JC Jr, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D.

    AIDS Res Hum Retroviruses. 2007 Feb;23(2):216-23.PMID: 17263650 [PubMed - indexed for MEDLINE]Related articles

    11.

    Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.

    Elion R, Cohen C, DeJesus E, Redfield R, Gathe J, Hsu R, Yau L, Ross L, Ha B, Lanier RE, Scott T; COL40263 Study Team.

    HIV Clin Trials. 2006 Nov-Dec;7(6):324-33.PMID: 17208898 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

    Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group.

    Clin Infect Dis. 2006 Nov 15;43(10):1337-46. Epub 2006 Oct 17.PMID: 17051503 [PubMed - indexed for MEDLINE]Related articles

    13.

    A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

    Johnson MA, Gathe JC Jr, Podzamczer D, Molina JM, Naylor CT, Chiu YL, King MS, Podsadecki TJ, Hanna GJ, Brun SC.

    J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):153-60.PMID: 16951643 [PubMed - indexed for MEDLINE]Related articles

    14.

    The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

    Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M; KLEAN study team.

    Lancet. 2006 Aug 5;368(9534):476-82. Erratum in: Lancet. 2006 Oct 7;368(9543):1238. PMID: 16890834 [PubMed - indexed for MEDLINE]Related articles

    15.

    Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

    Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

    Clin Ther. 2006 May;28(5):745-54.PMID: 16861096 [PubMed - indexed for MEDLINE]Related articles

    16.

    HAART at 10: an interview with Joseph Gathe.

    Gathe J.

    Res Initiat Treat Action. 2005 Summer;11(1):46-8. No abstract available. PMID: 16208820 [PubMed - indexed for MEDLINE]Related articles

    17.

    Beyond efficacy: the impact of combination antiretroviral therapy on quality of life.

    Sax PE, Gathe JC Jr.

    AIDS Patient Care STDS. 2005 Sep;19(9):563-76. Review.PMID: 16164383 [PubMed - indexed for MEDLINE]Related articles

    18.

    Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine.

    Musher DM, Ceasar H, Kojic EM, Musher BL, Gathe JC Jr, Romero-Steiner S, White AC Jr.

    J Infect Dis. 2005 Apr 1;191(7):1063-7. Epub 2005 Feb 28.PMID: 15747240 [PubMed - indexed for MEDLINE]Related articles

    19.

    Impact of resistance to antiretroviral therapy in the minority community.

    Rodriguez AE, Campo RE, Gathe JC Jr, Kwakwa HA.

    AIDS Read. 2004 Oct;14(10 Suppl):S9-11.PMID: 15497217 [PubMed - indexed for MEDLINE]Related articles

    20.

    SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

    Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J.

    AIDS. 2004 Jul 23;18(11):1529-37.PMID: 15238771 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    2 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity